There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nabriva (NBRV) and Intec Pharma Ltd (NTEC) with bullish sentiments.
Nabriva (NBRV)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Nabriva today and set a price target of $7. The company’s shares closed yesterday at $2.20.
Arce said:
“We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s).”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.8% and a 37.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nabriva with a $7.70 average price target, a 250.0% upside from current levels. In a report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $12.50 price target.
See today’s analyst top recommended stocks >>
Intec Pharma Ltd (NTEC)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Intec Pharma Ltd today and set a price target of $16. The company’s shares closed yesterday at $4.18, close to its 52-week low of $3.55.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 3.1% and a 33.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intec Pharma Ltd with a $15 average price target, a 258.9% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $15 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
